Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma

8 Oct 2019

Abstract excerpt

Plasma cells, the malignant cells in multiple myeloma (MM), express high levels of CD38. Daratumumab, the first CD38-targeting therapeutic antibody, is well tolerated and is effective both as monotherapy and in combination regimens. Daratumumab’s efficacy in cell lines, in ex vivo patient samples, and in the clinic correlates with expression of CD38 on pretreated myeloma cells [ 1 , 2 ]. There is a rapid but...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to Multiple Myeloma Research and Treatments
Share to Renal Transplantation Outcomes and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31595037
DOI: 10.1038/s41375-019-0587-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myelomaPMID 31595037Read ↗

Functional multi-omics reveals genetic and pharmacologic regulation of surface CD38 in multiple myelomaSemantic proximity Read ↗

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumabSemantic proximity Read ↗

Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaSemantic proximity Read ↗

Development of Gene Expression–Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation InhibitorsSemantic proximity Read ↗

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with DaratumumabSemantic proximity Read ↗

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myelomaSemantic proximity Read ↗

The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapseSemantic proximity Read ↗

Ablation of CD38 in multiple myeloma cells leads to an aggressive phenotype in a mouse xenograft model.Semantic proximity Read ↗

Potential role of daratumumab in the treatment of multiple myelomaSemantic proximity Read ↗

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple MyelomaSemantic proximity Read ↗

IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and AiolosSemantic proximity Read ↗

Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.